<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39319115</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2211-3355</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Preventive medicine reports</Title><ISOAbbreviation>Prev Med Rep</ISOAbbreviation></Journal><ArticleTitle>Post-COVID changes and disparities in cardiovascular mortality rates in the United States.</ArticleTitle><Pagination><StartPage>102876</StartPage><MedlinePgn>102876</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102876</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pmedr.2024.102876</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The COVID-19 pandemic disrupted healthcare delivery and increased cardiovascular morbidity and mortality. This study assesses whether cardiovascular mortality rates in the US have recovered post-pandemic and examines the equity of this recovery across different populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We analyzed data from the CDC WONDER database, covering US residents' mortality from 2018-2023. We focused on cardiovascular diseases, categorized by ischemic heart disease (IHD), heart failure (HF), hypertensive diseases (HTN), and cerebrovascular disease. Age-adjusted mortality rates were calculated for three periods: pre-COVID (2018-2019), during COVID (2020-2021), and post-COVID (2022-2023), stratified by demographic and geographic variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Cardiovascular age-adjusted mortality rates increased by 5.9% during the pandemic but decreased by 3.4% post-pandemic, resulting in a net increase of 2.4% compared to pre-COVID levels. When compared to pre COVID age-adjusted mortality rates, post COVID IHD mortality age-adjusted mortality rates decreased by 5.0%, while cerebrovascular and HTN age-adjusted mortality rates increased by 5.9% and 28.5%, respectively. Men and younger populations showed higher increases in cardiovascular Age-adjusted mortality rates. Geographic disparities were notable, with significant reductions in cardiovascular mortality in the Northeast and increases in states like Arizona and Oregon.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The COVID-19 pandemic led to a surge in cardiovascular mortality, with partial recovery post-pandemic. Significant differences in mortality changes highlight the need for targeted healthcare interventions to address inequities across demographic and geographic groups.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobo</LastName><ForeName>Ofer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Hillel Yaffe Medical Center, Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Shivani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Metabolism, Digestion &amp; Reproduction Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts Heart Centre, St. Bartholomew's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutter</LastName><ForeName>Martin K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamas</LastName><ForeName>Mamas A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prev Med Rep</MedlineTA><NlmUniqueID>101643766</NlmUniqueID><ISSNLinking>2211-3355</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KK has acted as a consultant, speaker or received grants for investigator-initiated studies for Astra Zeneca, Bayer, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp &amp; Dohme, Boehringer Ingelheim, Oramed Pharmaceuticals, Pfizer, Roche, Daiichi-Sankyo and Applied Therapeutics. SM has received speaker Honoraria from Lilly and Sanofi, UK.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39319115</ArticleId><ArticleId IdType="pmc">PMC11419919</ArticleId><ArticleId IdType="doi">10.1016/j.pmedr.2024.102876</ArticleId><ArticleId IdType="pii">S2211-3355(24)00291-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bassett M.T., Chen J.T., Krieger N. Variation in racial/ethnic disparities in COVID-19 mortality by age in the United States: A cross-sectional study. PLoS Med. 2020;17(10):e1003402. Erratum. In: PLoS Med. 2021 Feb 4;18(2):e1003541. doi: 10.1371/journal.pmed.1003541. PMID: 33079941; PMCID: PMC7575091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575091</ArticleId><ArticleId IdType="pubmed">33079941</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, Provisional Mortality on CDC WONDER Online Database. Data are from the final Multiple Cause of Death Files, 2018-2021, and from provisional data for years 2022-2024, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10-provisional.html on Mar 31, 2024.</Citation></Reference><Reference><Citation>Chaganty S.S., Abramov D., Van Spall H.G.C., et al. Rural and urban disparities in cardiovascular disease-related mortality in the USA over 20 years; have the trends been reversed by COVID-19? Int. J. Cardiol. Cardiovasc. Risk Prev. 2023;30(19) doi: 10.1016/j.ijcrp.2023.200202. PMID: 37675096; PMCID: PMC10477062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcrp.2023.200202</ArticleId><ArticleId IdType="pmc">PMC10477062</ArticleId><ArticleId IdType="pubmed">37675096</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington R.A., Califf R.M., Balamurugan A., et al. Call to action: rural health: A presidential advisory from the American Heart Association and American Stroke Association. Circulation. 2020;141(10):e615–e644. doi: 10.1161/CIR.0000000000000753. Epub 2020 Feb 10 PMID: 32078375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000753</ArticleId><ArticleId IdType="pubmed">32078375</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K., Aroda V.R., Aschner P., et al. The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery. Lancet Diabetes Endocrinol. 2022;10(12):890–900. doi: 10.1016/S2213-8587(22)00278-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00278-9</ArticleId><ArticleId IdType="pmc">PMC9640202</ArticleId><ArticleId IdType="pubmed">36356612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobo O., Efraim R., Saada M., et al. The impact of lockdown enforcement during the SARSCoV-2 pandemic on the timing of presentation and early outcomes of patients with ST-elevation myocardial infarction. PLoS One. 2020;15(10):e0241149. PMID: 33095801; PMCID: PMC7584161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584161</ArticleId><ArticleId IdType="pubmed">33095801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobo O., Abramov D., Fudim M., et al. Has the first year of the COVID-19 pandemic reversed the trends in CV mortality between 1999 and 2019 in the United States? Eur. Heart J. Qual. Care Clin. Outcomes. 2023;9(4):367–376. doi: 10.1093/ehjqcco/qcac080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjqcco/qcac080</ArticleId><ArticleId IdType="pubmed">36442154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyalwazi A.N., Loccoh E.C., Brewer L.C., et al. Disparities in cardiovascular mortality between black and white adults in the United States, 1999 to 2019. Circulation. 2022;146(3):211–228. doi: 10.1161/CIRCULATIONAHA.122.060199. Epub 2022 Jul 18. PMID: 35861764; PMCID: PMC9310198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.060199</ArticleId><ArticleId IdType="pmc">PMC9310198</ArticleId><ArticleId IdType="pubmed">35861764</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Singh G.K. Monthly trends in self-reported health status and depression by race/ethnicity and socioeconomic status during the COVID-19 Pandemic, United States, April 2020 - May 2021. Ann. Epidemiol. 2021;63:52–62. doi: 10.1016/j.annepidem.2021.07.014. Epub 2021 Aug 4. PMID: 34358622; PMCID: PMC8435379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2021.07.014</ArticleId><ArticleId IdType="pmc">PMC8435379</ArticleId><ArticleId IdType="pubmed">34358622</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas A.M.K., Fudim M., Michos E.D., et al. Has mortality in the United States returned to pre-pandemic levels? An analysis of provisional 2023 data. J. Intern. Med. 2024;296(2):168–176. doi: 10.1111/joim.13811. Epub 2024 Jun 3 PMID: 38829151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13811</ArticleId><ArticleId IdType="pubmed">38829151</ArticleId></ArticleIdList></Reference><Reference><Citation>Polyakova M., Udalova V., Kocks G., et al. Racial disparities in excess all-cause mortality during the early COVID-19 pandemic varied substantially across states. Health Aff. (millwood). 2021;40(2):307–316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7996479</ArticleId><ArticleId IdType="pubmed">33523748</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A.L., Bakouny Z., Bhalla S., et al. Cancer care disparities during the COVID-19 pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell. 2020;38(6):769–770. doi: 10.1016/j.ccell.2020.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.023</ArticleId><ArticleId IdType="pmc">PMC7609043</ArticleId><ArticleId IdType="pubmed">33176161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidney S., Go A.S., Jaffe M.G., et al. Association between aging of the US population and heart disease mortality from 2011 to 2017. JAMA Cardiol. 2019;4(12):1280–1286. doi: 10.1001/jamacardio.2019.4187. PMID: 31663094; PMCID: PMC6822092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2019.4187</ArticleId><ArticleId IdType="pmc">PMC6822092</ArticleId><ArticleId IdType="pubmed">31663094</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkowiak M.P., Domaradzki J., Walkowiak D. Unmasking the COVID-19 pandemic prevention gains: excess mortality reversal in 2022. Public Health. 2023;223:193–201. doi: 10.1016/j.puhe.2023.08.004. Epub 2023 Sep 5 PMID: 37672832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2023.08.004</ArticleId><ArticleId IdType="pubmed">37672832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28(3):583–590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>